MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas aeruginosa (PsA) pulmonary infections. MRX-5, a...
Olight Launches Charity Campaigns in Support of Breast Cancer Awareness and Hurricane Relief
LORTON, Va., Oct. 18, 2024 /PRNewswire/ -- Olight, a brand committed to becoming a global leader in mid-to-high-end flashlights, introduced its charity initiatives dedicated to supporting breast cancer awareness and hurricane disaster relief this October. Olight Charity Sale During this campaign, all proceeds from sales of the Oclip Pink will be donated to breast cancer organizations worldwide....
Neurophet to host Symposium featuring renowned expert in Alzheimer’s disease treatment from the U.S.
- Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer's disease treatments such as 'Leqembi' and 'Kisunla' SEOUL, South Korea, Oct. 18, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company...
Xinhua Silk Road: 55th Zhangshu National Traditional Chinese Materia Medica Trade Fair held in E. China’s Jiangxi
BEIJING, Oct. 18, 2024 /PRNewswire/ -- The 55th Zhangshu National Traditional Chinese Materia Medica Trade Fair kicked off on October 16 in Zhangshu, a county-level city in east China's Jiangxi Province, featuring the participation of more than 1,000 pharmaceutical and healthcare enterprises from all over the country. At the opening ceremony, the International Organization for Standardization (ISO)...
LaNova Medicines Announces Initiation of Phase 1 Clinical Trial of Anti-PD-1/VEGF Bispecific Antibody LM-299 and Completion of $42 Million Series C1 Financing
Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition of tumor growth and well-tolerated safety profile IND for LM-299 in the US expected to be submitted in the second half of 2024 Proceeds from the completed Series C1 financing will be primarily used to advance the...
City microbes surviving on disinfectants, research reveals
New research shows microbes are evolving to resist cleaners used to eliminate them. It also identifies novel strains living in Hong Kong that were previously only found in Antarctic desert soil. SUZHOU, China, Oct. 18, 2024 /PRNewswire/ -- After the recent pandemic, our use of disinfectants has increased, but are our efforts to create sterile urban environments backfiring? A new...
111 to Announce Third Quarter 2024 Unaudited Financial Results on November 28, 2024 – Conference Call to Follow
SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S....
China Ping An Insurance Overseas (Holdings) Limited Raised Fund of USD 850 Million for Overseas Private Equity Investing
HONG KONG, Oct. 18, 2024 /PRNewswire/ -- China Ping An Insurance Overseas (Holdings) Limited, the main offshore investment and asset management platform of Ping An Insurance (Group) Company of China, Ltd. (2318.HK, 601318.SH), together with its subsidiaries ("PAOH" or "Ping An"), announces the successful closing of its third vintage of private equity fund program (the "Fund"). The Fund is...
Medeze Group Awarded Frost & Sullivan’s 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions
Medeze Group (Medeze) specializes in cutting-edge stem cell banking services, leveraging advanced cryopreservation techniques and pioneering therapies to enhance longevity and health outcomes. SAN ANTONIO, Oct. 18, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the stem cell banking and longevity industry and, based on its findings, recognizes Medeze with the 2024 Southeast Asia Company of the Year Award. Medeze is...
Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings
GOTHENBURG, Sweden, Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased by 3.5%, of which the organic increase was 0.2%, while the operating margin weakened compared with last year. The global market...
